HEALTHCARE
Global Biologics CDMO Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Biologics CDMO Market, By Cell Type (Mammalian, Microbial, and Others), Indication (Oncology, Auto-Immune Diseases, Infectious Diseases, Neurology, and Others), Product Type (Drug Product and Drug Substance), Molecule Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Hormones, and Others), Service (Clinical and Commercial), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global biologics CDMO market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
The Biologics Contract Development and Production Organization (CDMO) market is a subset of the pharmaceutical business that specializes in providing services for the development and production of biologic pharmaceuticals. Biologics are therapeutic items made from biological sources such as living organisms, cells, tissues, or recombinant DNA. These items frequently include vaccinations, monoclonal antibodies, recombinant proteins, gene treatments, and cell therapies.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Increasing demand for biologic drugs
- Accelerated drug development timelines
RESTRAINTS
- High development costs
- Intellectual property concern
OPPORTUNITIES
- Regulatory expertise and compliance
- Flexibility and scalability
CHALLENGES
- Quality and regulatory risks
- Supply chain vulnerabilities
SEGMENTATION
MARKET SEGMENTATION
- Cell Type
- Mammalian
- Microbial
- Others
- Indication
- Oncology
- Auto-Immune Diseases
- Infectious Diseases
- Neurology
- Others
- Product Type
- Drug Product
- Drug Substance
- Molecule Type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Hormones
- Others
- Service
- Clinical
- Commercial
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Boehringer Ingelheim Group
- Wuxi Biologics
- Samsung Biologics
- Lonza Group
- Fujifilm Diosynth Biotechnologies USA Inc.
- Toyobo Co. Limited
- Parexel International Corporation
- Icon PLC
- BINEX Co. Limited
- JRS Pharma
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Biologics CDMO Market, by Cell Type
- 3.2 Global Biologics CDMO Market, by Indication
- 3.3 Global Biologics CDMO Market, by Product Type
- 3.4 Global Biologics CDMO Market, by Molecule Type
- 3.5 Global Biologics CDMO Market, by Service
- 3.6 Global Biologics CDMO Market, by Geography
- 3.7 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Trend 1
- 5.1.2 Trend 2
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Increasing demand for biologic drugs
- 5.2.2 Accelerated drug development timelines
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High development costs
- 5.3.2 Intellectual property concern
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Regulatory expertise and compliance
- 5.4.2 Flexibility and scalability
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Quality and regulatory risks
- 5.5.2 Supply chain vulnerabilities
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL BIOLOGICS CDMO MARKET, BY CELL TYPE
- 6.1 Cell Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Biologics CDMO Market, by Cell Type (2019-2032)
- SECTION 7 - GLOBAL BIOLOGICS CDMO MARKET, BY INDICATION
- 7.1 Indication Summary
- 7.2 Market Attractive Index
- 7.3 Global Biologics CDMO Market, by Indication (2019-2032)
- SECTION 8 - GLOBAL BIOLOGICS CDMO MARKET, BY PRODUCT TYPE
- 8.1 Product Type Summary
- 8.2 Market Attractive Index
- 8.3 Global Biologics CDMO Market, by Product Type (2019-2032)
- SECTION 9 - GLOBAL BIOLOGICS CDMO MARKET, BY MOLECULE TYPE
- 9.1 Molecule Type Summary
- 9.2 Market Attractive Index
- 9.3 Global Biologics CDMO Market, by Molecule Type (2019-2032)
- SECTION 10 - GLOBAL BIOLOGICS CDMO MARKET, BY SERVICE
- 10.1 Service Summary
- 10.2 Market Attractive Index
- 10.3 Global Biologics CDMO Market, by Service (2019-2032)
- SECTION 11 - GLOBAL BIOLOGICS CDMO MARKET, BY GEOGRAPHY
- 11.1 Regional Summary
- 11.2 Market Attractive Index
- 11.3 Global Biologics CDMO Market, by Geography (2019-2032)
- SECTION 12 - NORTH AMERICA BIOLOGICS CDMO MARKET
- 12.1 North America Summary
- 12.2 Market Attractive Index
- 12.3 North America Biologics CDMO Market, by Cell Type (2019-2032)
- 12.4 North America Biologics CDMO Market, by Indication (2019-2032)
- 12.5 North America Biologics CDMO Market, by Product Type (2019-2032)
- 12.6 North America Biologics CDMO Market, by Molecule Type (2019-2032)
- 12.7 North America Biologics CDMO Market, by Service (2019-2032)
- 12.8 North America Biologics CDMO Market, by Country (2019-2032)
- 12.8.1 U.S.
- 12.8.2 Canada
- 12.8.3 Mexico
- 12.8.4 Rest of North America
- SECTION 13 - EUROPE BIOLOGICS CDMO MARKET
- 13.1 Europe Summary
- 13.2 Market Attractive Index
- 13.3 Europe Biologics CDMO Market, by Cell Type (2019-2032)
- 13.4 Europe Biologics CDMO Market, by Indication (2019-2032)
- 13.5 Europe Biologics CDMO Market, by Product Type (2019-2032)
- 13.6 Europe Biologics CDMO Market, by Molecule Type (2019-2032)
- 13.7 Europe Biologics CDMO Market, by Service (2019-2032)
- 13.8 Europe Biologics CDMO Market, by Country (2019-2032)
- 13.8.1 Germany
- 13.8.2 U.K.
- 13.8.3 France
- 13.8.4 Italy
- 13.8.5 Spain
- 13.8.6 Russia
- 13.8.7 The Netherlands
- 13.8.8 Belgium
- 13.8.9 Turkey
- 13.8.10 Rest of Europe
- SECTION 14 - ASIA-PACIFIC BIOLOGICS CDMO MARKET
- 14.1 Asia-Pacific Summary
- 14.2 Market Attractive Index
- 14.3 Asia-Pacific Biologics CDMO Market, by Cell Type (2019-2032)
- 14.4 Asia-Pacific Biologics CDMO Market, by Indication (2019-2032)
- 14.5 Asia-Pacific Biologics CDMO Market, by Product Type (2019-2032)
- 14.6 Asia-Pacific Biologics CDMO Market, by Molecule Type (2019-2032)
- 14.7 Asia-Pacific Biologics CDMO Market, by Service (2019-2032)
- 14.8 Asia-Pacific Biologics CDMO Market, by Country (2019-2032)
- 14.8.1 China
- 14.8.2 India
- 14.8.3 Japan
- 14.8.4 South Korea
- 14.8.5 Singapore
- 14.8.6 Malaysia
- 14.8.7 Australia
- 14.8.8 Thailand
- 14.8.9 Philippines
- 14.8.10 Rest of Asia-Pacific
- SECTION 15 - SOUTH AMERICA BIOLOGICS CDMO MARKET
- 15.1 South America Summary
- 15.2 Market Attractive Index
- 15.3 South America Biologics CDMO Market, by Cell Type (2019-2032)
- 15.4 South America Biologics CDMO Market, by Indication (2019-2032)
- 15.5 South America Biologics CDMO Market, by Product Type (2019-2032)
- 15.6 South America Biologics CDMO Market, by Molecule Type (2019-2032)
- 15.7 South America Biologics CDMO Market, by Service (2019-2032)
- 15.8 South America Biologics CDMO Market, by Country (2019-2032)
- 15.8.1 Brazil
- 15.8.2 Argentina
- 15.8.3 Chile
- 15.8.4 Colombia
- 15.8.5 Rest of South America
- SECTION 16 - MIDDLE EAST AND AFRICA BIOLOGICS CDMO MARKET
- 16.1 Middle East and Africa Summary
- 16.2 Market Attractive Index
- 16.3 Middle East and Africa Biologics CDMO Market, by Cell Type (2019-2032)
- 16.4 Middle East and Africa Biologics CDMO Market, by Indication (2019-2032)
- 16.5 Middle East and Africa Biologics CDMO Market, by Product Type (2019-2032)
- 16.6 Middle East and Africa Biologics CDMO Market, by Molecule Type (2019-2032)
- 16.7 Middle East and Africa Biologics CDMO Market, by Service (2019-2032)
- 16.8 Middle East and Africa Biologics CDMO Market, by Country (2019-2032)
- 16.8.1 Kingdom of Saudi Arabia
- 16.8.2 South Africa
- 16.8.3 U.A.E.
- 16.8.4 Egypt
- 16.8.5 Rest of Middle East and Africa
- SECTION 17 - COMPANY SHARE ANALYSIS
- 17.1 Global Biologics CDMO Market, Company Share Analysis
- 17.2 North America Biologics CDMO Market, Company Share Analysis
- 17.3 Europe Biologics CDMO Market, Company Share Analysis
- 17.4 Asia-Pacific Biologics CDMO Market, Company Share Analysis
- SECTION 18 - COMPANY PROFILES
- 18.1 Boehringer Ingelheim Group
- 18.1.1 Company Snapshot
- 18.1.2 Financial Overview
- 18.1.3 Product Portfolio
- 18.1.4 Recent Developments
- 18.2 Wuxi Biologics
- 18.2.1 Company Snapshot
- 18.2.2 Financial Overview
- 18.2.3 Product Portfolio
- 18.2.4 Recent Developments
- 18.3 Samsung Biologics
- 18.3.1 Company Snapshot
- 18.3.2 Financial Overview
- 18.3.3 Product Portfolio
- 18.3.4 Recent Developments
- 18.4 Lonza Group
- 18.4.1 Company Snapshot
- 18.4.2 Financial Overview
- 18.4.3 Product Portfolio
- 18.4.4 Recent Developments
- 18.5 Fujifilm Diosynth Biotechnologies USA Inc.
- 18.5.1 Company Snapshot
- 18.5.2 Financial Overview
- 18.5.3 Product Portfolio
- 18.5.4 Recent Developments
- 18.6 Toyobo Co. Limited
- 18.6.1 Company Snapshot
- 18.6.2 Financial Overview
- 18.6.3 Product Portfolio
- 18.6.4 Recent Developments
- 18.7 Parexel International Corporation
- 18.7.1 Company Snapshot
- 18.7.2 Financial Overview
- 18.7.3 Product Portfolio
- 18.7.4 Recent Developments
- 18.8 Icon PLC
- 18.8.1 Company Snapshot
- 18.8.2 Financial Overview
- 18.8.3 Product Portfolio
- 18.8.4 Recent Developments
- 18.9 BINEX Co. Limited
- 18.9.1 Company Snapshot
- 18.9.2 Financial Overview
- 18.9.3 Product Portfolio
- 18.9.4 Recent Developments
- 18.10 JRS Pharma
- 18.10.1 Company Snapshot
- 18.10.2 Financial Overview
- 18.10.3 Product Portfolio
- 18.10.4 Recent Developments
- SECTION 19 - RELATED REPORTS
- SECTION 20 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.